Drug Type Small molecule drug |
Synonyms (+)-norcisapride, Norcisapride |
Target |
Action agonists |
Mechanism 5-HT3 receptor agonists(5-hydroxytryptamine receptors, ionotropic (HTR3) agonists), 5-HT4 receptor agonists(Serotonin 4 (5-HT4) receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H20ClN3O3 |
InChIKeyOMLDMGPCWMBPAN-YPMHNXCESA-N |
CAS Registry202590-69-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bulimia Nervosa | Phase 2 | Global | - | - |
Gastroesophageal Reflux | Phase 2 | United States | - | - |
Gastroesophageal Reflux | Phase 2 | - | - | |
Gastroesophageal Reflux | Phase 2 | - | - | |
Irritable Bowel Syndrome | Phase 2 | Global | - | - |